About upadacitini b
Selective JAK1 inhibitor
Used for
- Rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
- Atopic dermatitis and non-radiographic axial spondyloarthritis
- Ulcerative colitis and Crohn’s disease
Usual adult dose
Usually 15 mg once daily for arthritis, dermatitis, and axial spondyloarthritis. Inflammatory bowel disease treatment starts at 45 mg daily, then usually 15 or 30 mg daily.
Usual dose in children
Atopic dermatitis: age 12 years and older, usually 15 mg once daily; some need 30 mg. Juvenile arthritis: age 2 years and older, dose depends on weight and formulation.
Common side effects
- Upper respiratory infections, acne, nausea, and headache
- Herpes zoster and other infections
- Raised cholesterol or liver enzymes
- Blood clots and serious cardiovascular events
Important warnings
- Can cause serious infections, including tuberculosis; screening is needed before treatment.
- May increase risks of cancer, blood clots, major heart problems, and death.
- Avoid live vaccines during treatment; monitor blood counts, liver tests, and cholesterol.
- Not recommended with other JAK inhibitors, biologic immunosuppressants, or potent immunosuppressants.
Pregnancy
May harm an unborn baby; avoid use during pregnancy. Effective contraception is advised during treatment and for four weeks afterward.
Breastfeeding
Avoid breastfeeding during treatment and for six days after the last dose.
Interactions
- Strong CYP3A4 inhibitors can increase upadacitinib exposure.
- Strong CYP3A4 inducers can reduce its effectiveness.
- Avoid combination with biologic immunosuppressants or other JAK inhibitors.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.